Skip to main content
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. — Investor Relations & Filings

Ticker · ACRV ISIN · US0048901096 US Manufacturing
Open in API
Filings indexed 293 across all filing types
Latest filing 2025-04-25 Proxy Solicitation & In…
Country US United States of America
Listing US ACRV

About Acrivon Therapeutics, Inc.

https://acrivon.com/

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company's core technology is its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which uses proteomics to identify the biologic drivers of cancer in individual patients. This platform enables the development of OncoSignature companion diagnostic tests designed to match patients with therapies predicted to be most effective for their specific tumor biology, a method distinct from genomic-based approaches. Acrivon's pipeline focuses on DNA Damage Response and cell cycle regulators. Its lead drug candidate, ACR-368 (prexasertib), is a selective kinase inhibitor in Phase 2 clinical trials for multiple solid tumor types. The pipeline also includes ACR-2316, a dual WEE1/PKMYT1 inhibitor. The company leverages its AP3 platform for internal drug development and for strategic co-development partnerships.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes details about the Annual Meeting of Stockholders, voting instructions, director nominations, and ratification of the independent auditor. The document is titled 'Definitive Additional Materials' related to the proxy statement and contains no financial statements or detailed financial analysis. It is not the Annual Report itself but proxy solicitation materials for shareholder voting. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length is 3811 characters, which is consistent with a proxy statement or related materials rather than a full annual report or earnings release.
2025-04-25 English
DEF 14A
Proxy Solicitation & Information Statement
2025-04-25 English
Director's Dealing 2025
Director's Dealing
2025-04-21 English
Director's Dealing 2025
Director's Dealing
2025-04-18 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 7, 2025. It announces the appointment of a new Chief Medical Officer, Mansoor Raza Mirza, M.D., effective April 9, 2025. The content focuses on a management change and includes a press release as an exhibit. There are no financial statements or detailed financial data presented. The primary purpose is to disclose a change in senior management. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 3586 characters, which is relatively short and consistent with a management change announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2025-04-07 English
Director's Dealing 2025
Director's Dealing
2025-04-03 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.